CT-INDUSTRIAL-FLOW
18.10.2021 13:08:11 CEST | Business Wire | Press release
Leading industrial pumping solutions provider Industrial Flow Solutions ™, headquartered in New Haven, Conn., USA, announced today the agreement to acquire Clearwater Controls Ltd. ™, based in Glasgow, Scotland. Clearwater Controls offers a broad line of wastewater solutions, beginning with its leading deragging intelligent systems to solve specific pumping problems, to more advanced monitoring technology to optimize and manage entire water networks. Terms of the acquisition were not disclosed. Clearwater Controls will retain its company name and brand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005200/en/
Clearwater Controls is known worldwide for the DERAGGER ™+ line of intelligent deragging control systems. The company is bringing the Internet of Things (IoT) to industry sectors with its newest innovation: cloud-based data analytics and management for improved monitoring of water networks.
Clearwater Controls’ solutions allow engineers and operators to analyze and create baseline data on the performance of their pump networks in real time to optimize operations, identify problems, perform money-saving predictive maintenance, and avoid potentially harmful and costly environmental impacts. These smart interventions will transform the industry from its historic reactive approach to a predictive asset management model.
Incorporating Clearwater Controls’ DERAGGER PRO pump station controller across its brands will bring intelligent efficiency to nearly all product lines of Industrial Flow Solutions, particularly the innovative OverWatch™ Direct In-Line Pumping System platform. Clearwater Controls’ complementary products and technology will provide greater value to customers seeking to reduce startup time, strengthen reliability and provide real-time cloud-based data.
“As technology and smart data bring new changes to the water industry, this acquisition will establish Industrial Flow Solutions and Clearwater Controls as leaders in the new digital revolution,” said John Wilson, President of Industrial Flow Solutions. “This new partnership supports our combined missions to transform any industry that relies on high usage of water and the need for treatment,“ he added.
Wilson expects a dramatic increase in Clearwater Controls’ business as it develops a greater product range for the DERAGGER+ and expands its global customer base.
“This acquisition is of mutual benefit to both companies, making each uniquely more competitive. We have common values of being customer focused, highly responsive, innovative, collaborative, supportive, and ambitious,” Wilson said. “We will provide Clearwater Controls with resources and expertise to strengthen its business overall. Reciprocally, Clearwater Controls’ unique and agnostic control solutions open a huge opportunity for Industrial Flow Solutions to access a worldwide market,” Wilson added.
“Clearwater Controls is taking the lead in seizing the groundswell of interest and momentum around intelligent monitoring and management of wastewater networks,” said Simon Crompton, Managing Director, Clearwater Controls. “Our partnership with Industrial Flow Solutions provides us with a greater footprint to advance pumping technology worldwide,” said Crompton.
About Industrial Flow Solutions
Industrial Flow Solutions specializes in the design, manufacturing, sales and service of pumping and fluid management solutions for harsh, rugged environments. With OverWatch™ direct in-line pump systems, BJM Pumps® products and Stancor® Pumps and Controls, the company offers a comprehensive portfolio of submersible and direct in-line pumps and controls ideal for industrial, commercial and municipal wastewater applications. Industrial Flow Solutions, headquartered in New Haven, Conn., is a portfolio company of May River Capital , a Chicago-based private-equity firm focused on lower middle-market industrial growth companies. For more information, please visit https://flowsolutions.com .
About Clearwater Controls Ltd.
Clearwater Controls launched in 2009 as the research and development division of ID Systems. The company has conceived, developed, and delivered a suite of intelligent pump monitoring and anti-ragging solutions, built around its unique and patented technology. Based in Glasgow, Scotland, United Kingdom, with a rapidly expanding operation in the United States, Clearwater Controls delivers solutions to clients across the UK, Ireland, Continental Europe, and North America. For more information, please visit https://clearwatercontrols.co.uk .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005200/en/
Link:
Social Media:
https://www.facebook.com/Industrial-Flow-Solutions-102601071895549
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom